The earnings call for MiNK Therapeutics was predominantly positive, highlighting significant clinical trial successes, strategic partnerships, and advancements in manufacturing capabilities. While there was an increase in net loss, the company's financial strategy and strong leadership suggest a positive outlook for future growth.

Company Guidance

During the third quarter 2025 conference call for MiNK Therapeutics, Inc., significant progress was discussed, especially concerning their INKT cell therapy platform. The updated clinical trial data for AGENT-797, used both alone and in combination with anti-PD-1 in patients with relapsed or refractory solid tumors, showed remarkable results, including a median overall survival of approximately 23 months, with some cases achieving complete remission. The therapy demonstrated durable responses across various cancer types and was noted for its lack of severe toxicities, with mild fatigue being the most common side effect. Financially, MiNK ended the quarter with a cash balance of $14.3 million, raising an additional $1.2 million through an at-the-market sales agreement. The net loss for the quarter was $2.9 million, reflecting an increase from the previous year due to ongoing support of AGENT-797 programs. Looking ahead, the company is preparing for a global Phase two trial in acute pulmonary dysfunction and advancing their graft-versus-host disease (GVHD) study, supported by public-private partnerships and federal grants.

Successful Clinical Trials and Data

MiNK Therapeutics presented updated clinical data from their ongoing trial of AGENT-797, demonstrating a median overall survival of approximately 23 months in a refractory setting with patients who had heavily pretreated immune therapy-resistant solid tumors. Complete remission was observed in a patient with metastatic testicular cancer and durable partial response in second-line gastric cancer.

Strategic Partnerships and Grants

MiNK has established partnerships with the University of Wisconsin Carbone Cancer Center and received major public-private grants from the Department of Defense and NIH STTR awards to support their work in graft-versus-host disease and stem cell transplantation.

Manufacturing and Financial Strength

The company has increased its manufacturing capabilities, producing billions of cells per donor, and has a stable cash balance of $14.3 million, with additional fundraising extending their runway through 2026.

Leadership and Board Appointments

MiNK strengthened its leadership with the appointment of Dr. John Holcomb to the Board of Directors and Dr. Terese Hammond as a key member leading several critical programs.

MiNK Therapeutics (INKT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INKT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 24, 2026	2025 (Q4)	-0.89 / -	-0.62	―	―	―
Nov 14, 2025	2025 (Q3)	-0.85 / -0.65	-0.5	-30.00% (-0.15)	―
Aug 14, 2025	2025 (Q2)	-0.55 / -1.06	-0.7	-51.43% (-0.36)	―
May 15, 2025	2025 (Q1)	-0.61 / -0.70	-1.1	36.36% (+0.40)	―
Mar 18, 2025	2024 (Q4)	-0.49 / -0.62	-1.6	61.25% (+0.98)	―
Nov 14, 2024	2024 (Q3)	-0.80 / -0.50	-1.5	66.67% (+1.00)	―
Aug 13, 2024	2024 (Q2)	-0.98 / -0.70	-1.8	61.11% (+1.10)	―
May 14, 2024	2024 (Q1)	-1.52 / -1.10	-1.7	35.29% (+0.60)	―
Mar 21, 2024	2023 (Q4)	-1.52 / -1.60	-2.3	30.43% (+0.70)	―
Nov 09, 2023	2023 (Q3)	-1.82 / -1.50	-1.9	21.05% (+0.40)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INKT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 14, 2025	$13.22	$12.75	-3.56%
Aug 14, 2025	$17.50	$15.32	-12.46%
May 15, 2025	$7.50	$7.18	-4.27%
Mar 18, 2025	$8.52	$8.24	-3.29%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MiNK Therapeutics (INKT) report earnings?

MiNK Therapeutics (INKT) is schdueled to report earning on Mar 24, 2026, Before Open (Confirmed).

What is MiNK Therapeutics (INKT) earnings time?

MiNK Therapeutics (INKT) earnings time is at Mar 24, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INKT EPS forecast?

INKT EPS forecast for the fiscal quarter 2025 (Q4) is -0.89.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing